1Muijsers RB, Goa KL. Balsalazide:A review of its therapeutic use in mild-to-moderate ulcerative colitis. Drugs, 2002,62(11):1689
2Malchow H, Gertz B. A new mesalazine foam enema (Claversal Foam) compared with a standard liquid enema in patients with active distal ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2002,16(3):415
3Lindgren S, Lofberg R, Bergholm L. Effect of budesonide enema on remission and relapse rate in distal ulcerative colitis and proctitis. Scandinavian Journal of Gastroenterology, 2002,37(6):705
4Okamura S,Aoki H, Ohashi S, et al.Efficacy of cyclosporin with corticotropin for refractory ulcerativecolitis. Hepato-gastroenterology,2003,50(49):91
5Falasco G,Zinicola R,Forbes A,et al. Review article:Immunosuppressants in distal ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2002,16(2):181
6Skelly, Macvem LR, Jenkins A, et al. Toxicity of mycophenolate mofetil in patients with inflammatory bowel disease.Inflammatory Bowel Diseases, 2002, 8(2): 93
7Bariol C, Meagher AP, Vickers CR,et al. Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease.Journal of Gastroenterology and Hepatology,2002,17(2):135
8Schmidt C,Marth T, Wittig BM,et al. Interleukin-12 antagonists as new therapeutic agents in inflammatory bowel disease. Pathobiology,2002,70 (3):177
9Musch E,Andus T,Malek M.Induction and maintenance of clinical remission by interferon-beta in patients with steroid-refractory active ulcerative colitis-an open long-term pilot trial. Alimentary Pharmacology and Therapeutics,2002,16(7):1233
10Madsen SM,Schlichting P, Davidsen B, et al. An open-labeled,randomized study comparing systemic intefferon-alpha-2A and prednisolone enemas in the treatment of left-sided ulcerative colitis. The American Journal of Gastroenterology,2001,96(6):1807
3Guideline on the development of new medicinal products for the treatment of ulcerative colitis[EB/OL] . http: //www. emea. europa.eu/pdfs/human/ewp/ 1546306 endraft.pdf.
